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ABSTRACT 
With the high prevalence and high mortality rate of cancer in the global community, it is 
increasingly essential to accelerate our understanding of the disease, to identify new 
genetic targets for therapy, and to pursue avenues for improving on the therapies in 
development and in current use.  The aim of this study is to identify cell cycle-related 
genes whose expression is influenced by the chemotherapeutic drugs curcumin, SAHA, 
lycopene and thalidomide in breast and colon cancer and normal cell lines.  These drugs 
are currently not in clinical use for cancer in South Africa, and while there have been 
investigative studies of these chemotherapeutic agents, this study aims to identify the 
specific genes that are influenced by the drugs.  The result of this is that several genes 
that were not previously documented as targets of these drugs are highlighted.  The cell 
cycle pathway is the area of focus as loss of regulation in the cell cycle is one of the 
important factors involved in promoting cancer initiation and progression.   
 
In the first instance, flow cytometry was used to identify optimal drug concentrations 
relative to the cell cycle stages.  Following this, alterations in gene expression were 
assessed using a PCR-based differential display after each drug treatment.  Subsequently, 
a more focussed approach was taken in a PCR-array analysis of panels of cell cycle-
related genes. 
 
A subset of genes is identified that is implicated in oncogenic transformation in breast 
cancer.  This has the potential to inhibit the genetic pathways involved in breast 
malignancy by providing targets that perhaps may not be manipulated in current 
 iv 
therapies.  The gene expression studies here suggest that lycopene and thalidomide 
function in inhibiting this transformation, and play significant roles in suppressing the 
oncogenic state of breast cancer.  Curcumin and SAHA also exhibit important functions 
in inhibiting tumourigenesis in colon cancer.  While the results propose that the drugs 
have clear roles in inhibiting breast and colon cancer, they are also implicated in 
promoting cancer.  This research has defined the genes that must be carefully monitored 
during drug administering as they may promote these and other cancers.  The availability 
of these results to researchers will aid in selecting the criteria for assessing the success 
rate of these drugs. 
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